Physician profile
Larry Gitelman
NPI 1568438539
$3,406.61
in general payments reported to CMS, 2019-2025
24 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $767 · 2022: $952 · 2023: $708 · 2024: $571 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $846.42 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $630.71 | 2021-2025 | Spravato |
| Abbvie INC. | $483.74 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $410.21 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $283.74 | 2021-2022 | |
| Alkermes, INC. | $233.27 | 2023-2025 | Lybalvi, Aristada |
| Jazz Pharmaceuticals INC. | $91.38 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.12 | 2021-2023 | Tradjenta, Synjardy, Jardiance |
| Esperion Therapeutics, INC. | $34.55 | 2024 | Nexletol |
| Lilly USA, LLC | $33.48 | 2024 | Mounjaro |
| Currax Pharmaceuticals LLC | $28.51 | 2022-2023 | Onzetra Xsail, Contrave |
| Verona Pharma, INC. | $28.29 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $25.78 | 2021 | |
| Merck Sharp & Dohme LLC | $25.77 | 2021-2023 | Verquvo, Belsomra |
| Viatris Specialty LLC | $23.54 | 2025 | Yupelri |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $21.31 | 2023 | Uzedy |
| Novo Nordisk INC | $18.41 | 2025 | Wegovy |
| Scynexis, INC. | $18.41 | 2022 | |
| Avanir Pharmaceuticals, INC. | $17.20 | 2022 | |
| Pfizer INC. | $16.16 | 2023 | |
| Sanofi Pasteur INC. | $15.80 | 2023 | |
| Amarin Pharma, INC. | $13.97 | 2021 | |
| Philips North America LLC | $13.97 | 2021 | |
| Dexcom, INC. | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Gitelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.